366 related articles for article (PubMed ID: 23020119)
1. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
2. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
[TBL] [Abstract][Full Text] [Related]
3. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Colamartino M; Santoro M; Duranti G; Sabatini S; Ceci R; Testa A; Padua L; Cozzi R
Neurotox Res; 2015 Feb; 27(2):106-17. PubMed ID: 25355370
[TBL] [Abstract][Full Text] [Related]
5. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
6. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
[TBL] [Abstract][Full Text] [Related]
7. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
9. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
10. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Ren LQ; Wienecke J; Hultborn H; Zhang M
J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
14. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
15. L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells.
Rodríguez-Martín E; Canals S; Casarejos MJ; de Bernardo S; Handler A; Mena MA
J Neurochem; 2001 Aug; 78(3):535-45. PubMed ID: 11483656
[TBL] [Abstract][Full Text] [Related]
16. The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
Lazzara CA; Riley RR; Rane A; Andersen JK; Kim YH
Brain Res; 2015 Oct; 1622():127-36. PubMed ID: 26119916
[TBL] [Abstract][Full Text] [Related]
17. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
18. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
[No Abstract] [Full Text] [Related]
19. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
20. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Ciesielska A; Sharma N; Beyer J; Forsayeth J; Bankiewicz K
PLoS One; 2015; 10(4):e0122708. PubMed ID: 25860990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
